Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors

Published:2021-10-20 Issue:1 Volume:32 Page:35-44
ISSN:0960-8931
Container-title:Melanoma Research
language:en
Short-container-title:

Author:

Mantia Charlene M.,Werner Lillian,Stwalley Brian,Ritchings Corey,Tarhini Ahmad A.,Atkins Michael B.,McDermott David F.,Regan Meredith M.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Dermatology,Oncology

Reference21 articles.

1. Overall survival with combined nivolumab and ipilimumab in advanced melanoma.;Wolchok;N Engl J Med,2017

2. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.;Hodi;Lancet Oncol,2016

3. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma.;Robert;J Clin Oncol,2018

4. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.;Hamid;Ann Oncol,2019

5. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.;Robert;Lancet Oncol,2019

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab;Clinical Genitourinary Cancer;2024-12

2. Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214;Journal for ImmunoTherapy of Cancer;2024-07

3. The driving mechanism and targeting value of mimicry between vascular endothelial cells and tumor cells in tumor progression;Biomedicine & Pharmacotherapy;2023-09

4. A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy;Clinical Cancer Research;2023-08-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3